Alignment Healthcare, Inc. ALHC R2KR3KPHARMA
Company Overview
Alignment Healthcare, Inc. operates a consumer-centric healthcare platform for seniors in the United States. It delivers customized healthcare experience to meet the needs of seniors through its Medicare Advantage plans. Alignment Healthcare, Inc. was founded in 2013 and is based in Orange, California.
Why Investors Should Care
Generates a return on equity of 20.0%, reflecting efficient use of shareholder capital.
Revenue has grown at a 31.8% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $3.95B (+46.1% YoY); net profit $-724.00K.
- Trailing 12 Months Year-on-year growth — revenue +31.6%, earnings +142.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 31.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 31.78% |
| 1 Year: | 31.60% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 142.90% |
Stock Price Performance
| 1 Year: | -8.27% |
| 6 Months: | -26.57% |
| 3 Months: | -11.91% |
| 1 Month: | +1.20% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.88 · Neutral
P/E of 71.26 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 20.0%.
- Compounding revenue at 31.8% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 71.3.
- Trading 44.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALHC Alignment Healthcare, Inc. R2KR3KPHARMA | 13.54 | 71.26 | $2.81B | 0.00% | 2.90% | 20.04% | 31.78% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 224.27M | 243.96M | 245.49M | 267.00M | 308.74M | 293.27M | 345.29M | 366.18M | 359.98M | 434.81M | 456.88M | 450.24M | - | - | - | - | 926.93M | 1.02B | 993.70M | 1.01B | 1.24B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 820.90M | 881.74M | 868.02M | 889.49M | 1.09B | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 106.03M | 133.55M | 125.67M | 123.31M | 144.48M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 111.42M | 110.80M | 117.99M | 133.59M | 128.98M | - |
| Operating Income | -5.12M | 12.59M | 15.06M | -52.66M | -40.49M | -41.45M | -36.48M | -6.65M | -33.41M | -32.49M | -23.66M | -29.76M | -41.11M | -18.38M | - | - | -5.39M | 22.75M | 7.68M | -10.28M | 15.50M | 42.10M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.24M | 29.86M | 15.67M | -2.45M | 23.36M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.95M | 3.95M | 3.95M | 3.95M | 4.06M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.33M | 18.88M | 3.73M | -14.23M | 11.44M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.00K | 3.22M | 2.00K | -3.23M | 25.00K | - |
| Net Income | -10.07M | 8.37M | 10.85M | -56.87M | -44.76M | -45.82M | -40.82M | -11.58M | -40.25M | -37.28M | -28.48M | -35.05M | -46.52M | -24.01M | - | - | -9.11M | 15.67M | 3.73M | -11.01M | 11.42M | 36.56M |
| Diluted EPS | - | - | - | - | -0.25 | -0.26 | -0.23 | -0.06 | -0.22 | -0.20 | -0.15 | -0.19 | -0.25 | -0.13 | - | - | -0.05 | 0.07 | 0.02 | -0.05 | 0.05 | 0.17 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 753.97M | 955.39M | 1.17B | 1.43B | 1.82B | 2.70B | 3.95B |
| Cost of Revenue | - | - | - | 1.25B | 1.62B | 2.41B | 3.46B |
| Gross Profit | - | - | - | 184.28M | 201.03M | 296.69M | 488.56M |
| Operating Expenses | - | - | - | 312.92M | 328.85M | 398.25M | 473.81M |
| Operating Income | -29.48M | -5.26M | -178.07M | -128.64M | -127.82M | -101.56M | 14.75M |
| EBITDA | - | - | - | -113.53M | -105.30M | -77.44M | 45.32M |
| Interest Expense | - | - | - | 18.29M | 21.23M | 23.55M | 15.80M |
| Pretax Income | - | - | - | -149.30M | -148.19M | -128.05M | -958.00K |
| Tax Provision | - | - | - | 339.00K | -22.00K | 21.00K | 20.00K |
| Net Income | -44.73M | -22.93M | -195.29M | -149.55M | -148.02M | -128.03M | -724.00K |
| Diluted EPS | - | -0.15 | -1.14 | -0.83 | -0.79 | -0.67 | 0.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 338.50M | - | 633.86M | 591.88M | 782.06M | 1.07B |
| Current Assets | - | - | - | - | 544.55M | 483.54M | 661.64M | 951.58M |
| Cash & Equivalents | - | 86.48M | 207.31M | - | 409.55M | 202.90M | 432.86M | 575.82M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 92.89M | 119.75M | 153.90M | 253.21M |
| Total Liabilities | - | - | 307.89M | - | 394.56M | 433.81M | 681.11M | 886.51M |
| Current Liabilities | - | - | 153.45M | - | 229.96M | 263.02M | 351.85M | 556.87M |
| Long Term Debt | - | - | 144.17M | - | 160.90M | 161.81M | 321.43M | 323.18M |
| Total Debt | - | - | - | - | 164.60M | 170.79M | 329.26M | 329.64M |
| Total Equity | -33.66M | -78.71M | 30.61M | - | 238.13M | 156.95M | 99.85M | 179.28M |
| Shares Outstanding | - | - | - | - | 187.28M | 188.95M | 191.78M | 204.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 9.21M | 7.56M | - | -45.43M | -59.19M | 34.77M | 139.93M |
| Investing Cash Flow | -10.24M | -16.36M | - | -28.22M | -147.26M | 39.19M | -14.97M |
| Financing Cash Flow | 52.66M | 130.12M | - | 16.59M | 105.00K | 156.03M | 18.04M |
| Capital Expenditure | - | - | - | -23.77M | -35.99M | -41.42M | -26.78M |
| Free Cash Flow | - | - | - | -69.20M | -95.18M | -6.65M | 113.15M |
| Net Change in Cash | - | - | - | -57.05M | -206.34M | 229.99M | 142.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 12.8% | 11.0% | 11.0% | 12.4% |
| Operating Margin % | -3.9% | -0.6% | -15.3% | -9.0% | -7.0% | -3.8% | 0.4% |
| Net Margin % | -5.9% | -2.4% | -16.7% | -10.4% | -8.1% | -4.7% | -0.0% |
| ROE % | 56.8% | -74.9% | - | -62.8% | -94.3% | -128.2% | -0.4% |
| ROCE % | - | -2.8% | - | -31.8% | -38.9% | -23.6% | 2.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.32% | 19.34M | $263.45M |
| 2 | Wellington Management Group, LLP | 9.05% | 18.78M | $255.79M |
| 3 | FMR, LLC | 6.71% | 13.92M | $189.65M |
| 4 | T. Rowe Price Investment Management, Inc. | 6.32% | 13.12M | $178.69M |
| 5 | Vanguard Portfolio Management LLC | 5.63% | 11.67M | $158.98M |
| 6 | Invesco Ltd. | 5.00% | 10.37M | $141.18M |
| 7 | Bank of America Corporation | 4.51% | 9.35M | $127.30M |
| 8 | Vanguard Capital Management LLC | 3.93% | 8.14M | $110.92M |
| 9 | William Blair Investment Management, LLC | 3.74% | 7.76M | $105.71M |
| 10 | State Street Corporation | 3.52% | 7.30M | $99.39M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALHC
Alignment Healthcare (ALHC): Buy, Sell, or Hold Post Q2 Earnings?
Alignment Healthcare’s stock price has taken a beating over the past six months, shedding 27.6% of its value and falling to $13.68 per share. This may have investors wondering how to approach the situation.…
Alignment Healthcare to Present in Baird 2026 Global Healthcare Conference and Attend Morgan Stanley 24th Annual Global Healthcare Conference
ORANGE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will participate in and attend two upcoming healthcare conferences in New York: Presenting: Baird 2026 Global Healthcare Co…
ALHC Q2 Deep Dive: Investments in Clinical Innovation and Member Growth Drive Mixed Market Response
Health insurance company Alignment Healthcare (NASDAQ:ALHC) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 31.6% year on year to $1.34 billion. The company expects next quarter’s revenue to be around $1…
Alignment Healthcare Inc (ALHC) (Q2 2026) Earnings Call Highlights: Record Membership Growth ...
Alignment Healthcare Inc (ALHC) reports 31% membership growth and 32% revenue increase, while raising full-year 2026 guidance despite planned second-half investments.
Alignment Healthcare (ALHC) Q2 2026 Earnings Call Transcript
Health plan membership surged 31% as AI-powered care coordination drove margin expansion.
Compared to Estimates, Alignment Healthcare (ALHC) Q2 Earnings: A Look at Key Metrics
The headline numbers for Alignment Healthcare (ALHC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.…
ALHC — Frequently Asked Questions
What is the current share price of Alignment Healthcare, Inc. (ALHC)?
As of 2026-09-07 16:24 PDT, Alignment Healthcare, Inc. (ALHC) trades at $13.54 on NasdaqGS. Its 52-week range is $12.78 to $24.56.
What is the market capitalisation of ALHC?
Alignment Healthcare, Inc. (ALHC) has a market capitalisation of $2.81B on NasdaqGS.
What is the P/E ratio of ALHC?
ALHC trades at a trailing price-to-earnings (P/E) ratio of 71.26. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 11.23.
What is the return on equity (ROE) of ALHC?
ALHC has a return on equity (ROE) of 20.04%. Its return on capital employed (ROCE) is 2.90%.
Is ALHC a good stock to buy?
This page provides a data-driven analysis of Alignment Healthcare, Inc. (ALHC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.